CHICAGO, May 1, 2013 /PRNewswire/ -- Positron Corporation (OTCBB: POSC) is pleased to announce the release of the PosiRx® 3000-Series, its latest pharmacy automation systems. The PosiRx® 3000-Series are the first systems to automate and encompass the complete compounding process, from generator elution to dose distribution, of multiple diagnostic SPECT agents in an environment engineered to be ISO Class 5 and USP 797 compliant. Designed for facilities dispensing as many as three hundred patient-specific doses per day, the PosiRx® 3000-Series will benefit providers and patients by enabling unit dose radiopharmaceuticals to be prepared more cost effectively and accurately than previously possible.
The PosiRx® line of automation systems features DoseLink, Positron's state of the art proprietary software. Developed for precision and customer ease of use, DoseLink maximizes the functionality and efficiency of operating the PosiRx® system through a robust and intuitive interface that can be operated from a variety of interfaces. Whether accessed from a desktop, tablet or smartphone, DoseLink empowers the user to control drug preparation and plan daily production, as well as store and retrieve data in a secure environment. Additionally, the operator may interact with Positron support personnel for assistance with any task in real time, across any platform.
"The release of the PosiRx® 3000-Series is a true milestone that marks the next phase in nuclear pharmacy automation," stated Charles Conroy, RPh, MBA, Positron's Chief Operating Officer. "For over 20 years, the nuclear pharmacy community has been seeking an automation solution that can efficiently and accurately prepare patient specific unit doses. Through the ability to compound a wide selection of radiopharmaceuticals, coupled with the system's speed and efficiency, the 3000-Series is that solution and stands in a class by itself. By powering the System with DoseLink, PosiRx® users will benefit from the unprecedented flexibility and control to operate across all types of devices and a variety of platforms. By controlling the preparation process from any place at any time, our customers will see significant revenue enhancement from increased patient throughput and a decrease in cost of goods."
"We are pleased to continue Positron's 30-year legacy of innovation," stated Patrick G. Rooney, Positron's Chief Executive Officer, "As we begin the installations of multiple pre-ordered systems, we are excited to be the first to bring this revolutionary technology to market."
To support our commercialization efforts, Positron has launched a dedicated website for the PosiRx® portfolio of products, www.posirx.com. The new website is part of Positron's plan to further develop its corporate identity and is designed to help distinguish between the Company's cardiac PET business and high tech automation products. By highlighting innovative features and further expanding its capabilities, the site allows visitors to gain a comprehensive understanding of the PosiRx® System.
Conroy added, "The PosiRx® system with DoseLink software provides a solid platform for growth into other diagnostic areas, additional pharmaceutical classes and new markets. The dedicated website will be very important as we work with our partners to expand Positron's offerings."
About Positron: Positron Corporation is a nuclear medicine healthcare company vertically integrating key segments of nuclear cardiologyproviding an end-to-end solution for cardiac PET. Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. Positron is redefining the industry. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
SOURCE Positron Corporation